$10.36
4.11%
Nasdaq, Dec 26, 09:00 pm CET
ISIN
US31773D1019
Symbol
FNCH

Finch Therapeutics Group Inc Stock price

$10.87
-1.13 9.42% 1M
+9.53 711.19% 6M
+7.26 201.11% YTD
+7.33 207.06% 1Y
-304.43 96.55% 3Y
-499.13 97.87% 5Y
-499.13 97.87% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.51 4.96%
ISIN
US31773D1019
Symbol
FNCH
Sector

Key metrics

Market capitalization $17.45m
Enterprise Value $30.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.23
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-19.69m
Free Cash Flow (TTM) Free Cash Flow $-18.04m
Cash position $16.04m
EPS (TTM) EPS $-8.82
Short interest 2.76%
Show more

Is Finch Therapeutics Group Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Finch Therapeutics Group Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Finch Therapeutics Group Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Finch Therapeutics Group Inc:

Buy
100%

Financial data from Finch Therapeutics Group Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.18 0.18
96% 96%
-
-0.18 -0.18
95% 95%
-
- Selling and Administrative Expenses 19 19
44% 44%
-
- Research and Development Expense - -
-
-
-20 -20
73% 73%
-
- Depreciation and Amortization 0.18 0.18
96% 96%
-
EBIT (Operating Income) EBIT -20 -20
74% 74%
-
Net Profit -14 -14
90% 90%
-

In millions USD.

Don't miss a Thing! We will send you all news about Finch Therapeutics Group Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Finch Therapeutics Group Inc Stock News

Neutral
GlobeNewsWire
2 months ago
BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to delist the Company's common stock, par value $0.001 per share (the “Common...

Company Profile

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in September 2017 and is headquartered in Somerville, MA.

Head office United States
CEO Matthew Blischak
Employees 1
Founded 2014
Website www.finchtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today